Rallybio (RLYB) Competitors

CervoMed (NASDAQ:CRVO) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Do analysts recommend CRVO or RLYB?

CervoMed presently has a consensus price target of $23.71, suggesting a potential upside of 131.25%. Rallybio has a consensus price target of $10.00, suggesting a potential upside of 1,520.75%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Rallybio	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media prefer CRVO or RLYB?

In the previous week, CervoMed had 18 more articles in the media than Rallybio. MarketBeat recorded 21 mentions for CervoMed and 3 mentions for Rallybio. Rallybio's average media sentiment score of 0.96 beat CervoMed's score of 0.43 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rallybio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, CRVO or RLYB?

CervoMed has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of CRVO or RLYB?

25.2% of CervoMed shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 8.7% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has higher valuation and earnings, CRVO or RLYB?

CervoMed has higher revenue and earnings than Rallybio. CervoMed is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$9.74M	9.74	-$16.29M	-$2.61	-3.93
Rallybio	$640K	40.29	-$57.78M	-$0.94	-0.66

Is CRVO or RLYB more profitable?

CervoMed has a net margin of -290.72% compared to Rallybio's net margin of -5,473.33%. CervoMed's return on equity of -59.15% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-290.72%	-59.15%	-53.64%
Rallybio	-5,473.33%	-71.66%	-65.06%

Summary

CervoMed beats Rallybio on 11 of the 17 factors compared between the two stocks.